1. Home
  2. REGN
  3. REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on January 21, 2025

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
REGN

Insider Monkey

2 days ago

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
REGN

Zacks

4 days ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
REGN

Zacks

4 days ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
REGN

Fortune

5 days ago

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
REGN

Zacks

5 days ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

REGN

Investing.com

5 days ago

UBS cuts rating on Regeneron stock amid Eylea uncertainty

REGN

MT Newswires

5 days ago

UBS Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Cuts Price Target to $738 From $1,130

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
REGN

Insider Monkey

6 days ago

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
REGN

Simply Wall St.

6 days ago

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
REGN

Zacks

7 days ago

Regeneron Reports Eylea Sales, Provides Other Pipeline Updates

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint
REGN

Investor's Business Daily

7 days ago

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

REGN

MT Newswires

8 days ago

Jefferies Adjusts Regeneron Pharmaceuticals Price Target to $1,120 From $1,200

Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database
REGN

Medical Device Network

8 days ago

Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database

REGN

MT Newswires

8 days ago

Citigroup Cuts Regeneron Pharmaceuticals' Price Target to $795 From $895

Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint
REGN

Investor's Business Daily

8 days ago

Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint

Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
REGN

Zacks

8 days ago

Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?

REGN

MT Newswires

8 days ago

Regeneron Pharmaceuticals Invests $119.5 Million in Truveta to Launch Genome Project

REGN

MT Newswires

8 days ago

Regeneron Pharmaceuticals' Trial Shows Adjuvant Libtayo Improved Disease-Free Survival After Surgery in CSCC Patients

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
REGN

GlobeNewswire

8 days ago

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
REGN

GlobeNewswire

8 days ago

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
REGN

Reuters

8 days ago

Truveta sells stakes to Regeneron, Illumina in deal to build genetic database

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
REGN

GlobeNewswire

8 days ago

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again
REGN

Zacks

11 days ago

Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again

REGN

MT Newswires

11 days ago

Wells Fargo Cuts Price Target on Regeneron Pharmaceuticals to $900 From $1,050, Maintains Overweight Rating

REGN

MT Newswires

11 days ago

Oppenheimer Adjusts Regeneron Pharmaceuticals' Price Target to $950 From $1,000, Keeps Outperform Rating

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
REGN

Zacks

11 days ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

REGN

MT Newswires

13 days ago

Truist Trims Price Target on Regeneron Pharmaceuticals to $1,004 From $1,126, Keeps Buy Rating

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
REGN

GlobeNewswire

13 days ago

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

REGN

MT Newswires

14 days ago

RBC Trims Price Target on Regeneron Pharmaceuticals to $1,184 From $1,215, Keeps Outperform Rating

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
REGN

Pharmaceutical Technology

15 days ago

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder

1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
REGN

Motley Fool

19 days ago

1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street

Jim Cramer’s Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the Future
REGN

Insider Monkey

20 days ago

Jim Cramer’s Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the Future

Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years
REGN

Simply Wall St.

21 days ago

Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
REGN

Zacks

a month ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

REGN

MT Newswires

a month ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating

REGN

MT Newswires

a month ago

Regeneron Says Investigational Antibodies Show Antithrombotic Effects in Phase 2 Trial

Regeneron says study data support big bet on new blood thinners
REGN

BioPharma Dive

a month ago

Regeneron says study data support big bet on new blood thinners

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
REGN

GlobeNewswire

a month ago

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

REGN

Morningstar Research

a month ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
REGN

Zacks

a month ago

REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
REGN

Zacks

a month ago

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
REGN

GlobeNewswire

a month ago

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
REGN

The Wall Street Journal

a month ago

Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial

REGN

MT Newswires

a month ago

Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
REGN

GlobeNewswire

a month ago

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
REGN

Insider Monkey

a month ago

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
REGN

GlobeNewswire

a month ago

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
REGN

Zacks

a month ago

Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases

Regeneron Down 15.5% Year to Date: How to Play the Stock?
REGN

Zacks

a month ago

Regeneron Down 15.5% Year to Date: How to Play the Stock?

Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
REGN

Pharmaceutical Technology

a month ago

Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge

Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
REGN

Pharma Voice

a month ago

Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900
REGN

Insider Monkey

a month ago

Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900

Regeneron reinstated with an Underperform at BofA
REGN

TipRanks

a month ago

Regeneron reinstated with an Underperform at BofA

ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
REGN

Pharmaceutical Technology

a month ago

ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope

Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
REGN

GlobeNewswire

a month ago

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
REGN

GlobeNewswire

a month ago

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
REGN

Simply Wall St.

a month ago

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

REGN

MT Newswires

2 months ago

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $1,186 From $1,184, Maintains Overweight Rating

REGN

MT Newswires

2 months ago

Maia Biotechnology, Regeneron Expand Clinical Supply Deal

REGN

Morningstar Research

2 months ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Galderma Bets on Skin Drug to Turn Around Pharma Business
REGN

The Wall Street Journal

2 months ago

Galderma Bets on Skin Drug to Turn Around Pharma Business

Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy
REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
REGN

Investor's Business Daily

2 months ago

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

REGN

MT Newswires

2 months ago

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?
REGN

Zacks

2 months ago

Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?

Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds
REGN

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds

Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 15% CAGR over the last five years
REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 15% CAGR over the last five years

Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
REGN

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now

Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
REGN

Insider Monkey

2 months ago

Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
REGN

Zacks

2 months ago

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

REGN

MT Newswires

2 months ago

Deutsche Bank Cuts Regeneron Pharmaceuticals Price Target to $805 From $900, Maintains Hold Rating

REGN

Morningstar Research

2 months ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
REGN

Pharmaceutical Technology

2 months ago

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

REGN

MT Newswires

2 months ago

Wolfe Initiates Regeneron Pharmaceuticals at Outperform With $1,150 Price Target

REGN

MT Newswires

2 months ago

Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
REGN

GlobeNewswire

2 months ago

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

REGN

Investing.com

2 months ago

Citi initiates coverage on 5 new biotech stocks

REGN

Argus Research

2 months ago

Daily Spotlight: Argus Raises EPS Forecasts

2 Top Growth Stocks to Buy on the Dip
REGN

Motley Fool

2 months ago

2 Top Growth Stocks to Buy on the Dip

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
REGN

Benzinga

2 months ago

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
REGN

GlobeNewswire

2 months ago

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

Regeneron Announces Investor Conference Presentations
REGN

GlobeNewswire

2 months ago

Regeneron Announces Investor Conference Presentations

REGN

MT Newswires

2 months ago

Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,175

REGN

Argus Research

2 months ago

Analyst Report: Regeneron Phars, Inc

REGN

Argus Research

2 months ago

Market Digest: EXPE, FCX, HOLX, MRO, NOC, REGN, GEN, WBA, ANET

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease
REGN

Simply Wall St.

2 months ago

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

REGN

Morningstar Research

2 months ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer
REGN

TipRanks

2 months ago

Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
REGN

Pharmaceutical Technology

2 months ago

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

REGN

MT Newswires

2 months ago

Oppenheimer Adjusts Regeneron Pharmaceuticals Price Target to $1,000 From $1,150, Maintains Outperform Rating

REGN

MT Newswires

2 months ago

Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
REGN

Motley Fool

2 months ago

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
REGN

GlobeNewswire

2 months ago

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

REGN

MT Newswires

2 months ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $844,610, According to a Recent SEC Filing

Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
REGN

Simply Wall St.

3 months ago

Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Regeneron price target lowered to $1,126 from $1,137 at Truist
REGN

TipRanks

3 months ago

Regeneron price target lowered to $1,126 from $1,137 at Truist

REGN

MT Newswires

3 months ago

UBS Cuts Price Target on Regeneron Pharmaceuticals to $1,130 From $1,251, Maintains Buy Rating

What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
REGN

Insider Monkey

3 months ago

What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?

REGN

MT Newswires

3 months ago

Leerink Partners Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $1,077

Share on Social Networks: